RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune…
Browsing: Ideas & Technologies
Cible is a preclinical-stage cancer drug company that solves the major problems of traditional cancer therapy through the implementation of a smart drug platform. The first lead candidate, oxaliTEX, is found to be well tolerated, tumor localizing, and overcomes platinum drug resistance in pharmacological in vitro human cancer models. These…
Tosk is a dynamic drug development company dedicated to alleviating the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs…
TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to…
OTraces has developed a disruptive technology using math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer diagnostics. By using these techniques to access the active proteins found in the tumor microenvironment (TME) with, for the first time, simple and cost-effective blood based-tests, OTraces has solved the problem of…
SageMedic is creating a 3D micro-tumor assay to help physicians determine the best cancer treatment for their patient. To do so, we take a live tumor biopsy, create hundreds of 3D micro-tumors, expose them to a wide range of anti-cancer drugs (e.g. chemotherapy or targeted therapy), and measure the response…
Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology. The company’s proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most…
LADR™ Technology May Successfully Harness Potential of Known, Efficacious Anti-Cancer Compounds Whose Development Has Been Impeded CytRx Corporation (NASDAQ: CYTR), a Los Angeles-based biopharmaceutical research and development company specializing in oncology, recently selected four new investigational-stage Linker-Activated Drug Release (LADR™) candidates for advancement toward clinical testing in cancer patients. At…